Home › Funds › Trails Edge Capital Partners, LP › MLTX
Trails Edge Capital Partners, LP position in MLTX
MOONLAKE IMMUNOTHERAPEUTICS · Health Care
Trails Edge Capital Partners, LP reported holding 1,680,000 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$19.7M, representing 2.82% of its reported portfolio and ranking #17 among its reported holdings. Trails Edge Capital Partners, LP has disclosed MLTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Trails Edge Capital Partners, LP's MLTX position evolved
Trails Edge Capital Partners, LP first disclosed a stake in MLTX in Q2 2026 at 750,000 shares (US$14.6M). The position peaked in Q3 2026 at 1,680,000 shares, worth US$19.7M. Across 2 filings, Trails Edge Capital Partners, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,680,000 shares valued at US$19.7M — an increase of 930,000 shares quarter over quarter.. Notable position changes include a 124% increase in Q3 2026 (shares rose 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 750.00K | $14.60M | New |
| Q3 2026 | 1.68M | $19.66M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLTX and 13F data
MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 24 other funds we track also report a position in MLTX — the largest reported positions include BVF INC/IL (US$311.5M), Deep Track Capital, LP (US$94.8M), Cormorant Asset Management, LP (US$62.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLTX
- BVF INC/IL 16.00M sh · $311.54M · Q2 2026
- Deep Track Capital, LP 8.11M sh · $94.83M · Q3 2026
- Cormorant Asset Management, LP 3.21M sh · $62.41M · Q2 2026
- MPM BioImpact LLC 1.61M sh · $31.29M · Q2 2026
- Weiss Asset Management LP 2.34M sh · $27.39M · Q3 2026
- Logos Global Management LP 1.50M sh · $17.55M · Q3 2026
- GREAT POINT PARTNERS LLC 855.81K sh · $16.66M · Q2 2026
- Vivo Capital, LLC 1.40M sh · $16.38M · Q3 2026
More on Trails Edge Capital Partners, LP
FAQ
How long has Trails Edge Capital Partners, LP held MLTX?
Trails Edge Capital Partners, LP has disclosed MLTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Trails Edge Capital Partners, LP's current position in MLTX?
As of Q3 2026, Trails Edge Capital Partners, LP holds 1.68M shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $19.66M, representing 2.82% of its reported portfolio and ranking #17.
Has Trails Edge Capital Partners, LP been buying or selling MLTX?
In the latest 13F filing (Q3 2026), Trails Edge Capital Partners, LP increased its position in MLTX. The position peaked in Q3 2026 at 1.68M shares.
Which other funds hold MLTX?
Other major institutional holders of MLTX include BVF INC/IL, Deep Track Capital, LP, Cormorant Asset Management, LP, among 24 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.